| 重组人血管内皮抑制素联合化疗治疗晚期大肠癌的临床进展 |
| |
| 引用本文： | 滕弥明1,' target='_blank'>2,董洪敏1,' target='_blank'>2. 重组人血管内皮抑制素联合化疗治疗晚期大肠癌的临床进展[J]. 现代肿瘤医学, 2019, 0(7): 1269-1272. DOI: 10.3969/j.issn.1672-4992.2019.07.044 |
| |
| 作者姓名： | 滕弥明1 ' target='_blank'>2 董洪敏1 ' target='_blank'>2 |
| |
| 作者单位： | 1.贵州医科大学，贵州 贵阳 550004；2.贵州省肿瘤医院腹部肿瘤科，贵州 贵阳 550004 |
| |
| 摘 要： | 抗肿瘤血管生成疗法成为当今肿瘤生物靶向治疗领域的研究前沿，为临床治疗晚期肿瘤治疗带来新的希望。目前国产的重组人血管内皮抑素（恩度）联合化疗治疗多种实体肿瘤患者，取得了较好的确切的疗效。本文针对近年来临床应用恩度联合化疗治疗晚期大肠癌以及如何在合适的时间段使用恩度达到更好疗效的研究进展作一综述。
|
| 关 键 词： | 晚期大肠癌 恩度 抗血管生成治疗 肿瘤血管正常化 时间窗 |
Clinical progress of recombinant human vascular endotheliostatin combined with chemotherapy in the treatment of advanced colorectal cancer |
| |
| Teng Miming1,' target='_blank'>2,Dong Hongmin1,' target='_blank'>2. Clinical progress of recombinant human vascular endotheliostatin combined with chemotherapy in the treatment of advanced colorectal cancer[J]. Journal of Modern Oncology, 2019, 0(7): 1269-1272. DOI: 10.3969/j.issn.1672-4992.2019.07.044 |
| |
| Authors: | Teng Miming1 ' target='_blank'>2 Dong Hongmin1 ' target='_blank'>2 |
| |
| Affiliation: | 1.Guizhou Medcial University，Guizhou Guiyang 550004，China；2.Department of Abdomen Oncology，Guizhou Cancer Hospital，Guizhou Guiyang 550004，China. |
| |
| Abstract: | Anti-tumor angiogenesis therapy has become the research frontier in the field of tumor target therapy，which brings new hope for the clinical treatment of advanced tumors.Domestic recombinant human vascular endostatin(ENDOSTAR)combined chemotherapy for various solid tumor patients has achieved a good and accurate effect.This paper reviews the progress of clinical application of ENDOSTAR combined chemotherapy in the treatment of advan ced colorectal cancer and how to achieve better results in the appropriate time period. |
| |
| Keywords: | advanced colorectal cancer ENDOSTAR antiangiogenic therapy normalization of tumor blood vessels time window |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
